# DESCRIPTION

## TECHNICAL FIELD OF THE INVENTION

- relate to virus purification method

## BACKGROUND OF THE INVENTION

- describe HCV characteristics
- discuss HCV infection statistics
- motivate need for HCV vaccine
- limitations of current DSP methods

## SUMMARY OF THE INVENTION

- introduce improved DSP method
- application of purified virus particles

## DETAILED DESCRIPTION OF THE INVENTION

### Definitions

- define clarification
- define ultrafiltration
- define chromatography
- define SXC
- define SCMA
- define dynamic binding capacity (DBC)
- define virus particles
- define whole virus particles
- define isolate and strain
- define identity
- describe sequence identity calculation
- define adaptive mutation
- define composition
- define pharmaceutically acceptable
- define excipient
- define adjuvant
- define cell and cell systems
- define cell line
- describe DNA and RNA sequences
- describe primary cultures
- describe cell clones
- describe immortalized cells
- describe non-hepatic cell lines
- describe primary challenge
- describe antigen
- describe lymphoid system activator
- describe humoral immune response
- describe cellular immune response
- describe primary cultures
- describe cell lines
- describe cell clones
- describe immortalized cells
- describe non-hepatic cell lines
- describe primary challenge
- describe antigen
- describe lymphoid system activator
- describe humoral immune response
- describe cellular immune response
- describe primary cultures
- describe cell lines
- describe cell clones
- define elution buffer composition
- specify elution buffer conductivity range
- describe inert buffer composition
- specify PEG size and concentration
- introduce SCMA technique
- describe SCMA membrane properties
- specify SCMA flow rate
- outline method of purifying whole virus particles
- describe inactivation step
- specify inactivation methods
- describe nuclease treatment step
- specify nuclease treatment timing
- describe freezing step
- specify virus particle types
- describe virus particle families
- specify virus particle genotypes
- describe HCV particles
- specify HCV genotypes
- describe adaptive mutations
- specify amino acid mutations
- describe high-titre cell culture
- specify infectivity titers
- describe cell culture conditions
- specify cell line types
- describe methods for producing HCV particles
- describe replication level determination
- introduce pharmaceutical compositions
- describe whole virus vaccine candidate stock
- specify pharmaceutical composition formulation
- describe adjuvants
- specify adjuvant types
- describe use of whole virus particles
- describe preparation of whole virus vaccine candidate stock
- describe preparation of pharmaceutical composition

### EXAMPLES

- introduce Huh7.5 cell culture
- describe cell maintenance
- detail adenovirus expression medium
- evaluate HCV infected cells
- describe immunostaining
- determine HCV-infectivity titres
- perform serial passage for high-titre genotype La HCV
- describe production of genotype 1a and 5a HCV
- perform sequence analysis
- align amino acid sequences
- evaluate infectious HCV stability at alkaline pH values
- describe virus clarification and ultrafiltration
- perform inactivation
- describe nuclease treatment
- perform chromatographic purification
- describe virus capture using SXC
- detail SXC column preparation
- perform SXC runs
- describe virus polishing using SCMA
- detail SCMA column preparation
- perform SCMA runs
- determine dynamic binding capacities
- describe HCV quantification
- perform quantitative polymerase chain reaction
- describe protein determination
- perform BCA protein assay
- describe DNA determination
- perform PicoGreen dsDNA assay
- describe ultracentrifugation-based downstream process
- detail ultracentrifugation procedure
- describe cross-flow filtration
- perform gradient ultracentrifugation
- describe Sephadex G-100 chromatography
- detail UV irradiation
- describe production of high-titre genotype La virus stock
- detail serial passage of genotype 1a virus
- perform next generation sequencing
- describe HCV clarification and ultrafiltration
- detail inactivation
- describe HCV capture by SXC
- evaluate SXC performance
- introduce HCV purification
- test alkaline SXC conditions
- investigate HCV stability at different pH values
- determine dynamic binding capacity of membranes
- analyze impurity removal
- conclude HCV purification by SXC
- introduce SCMA chromatography
- study effect of SCMA on SXC elution
- analyze virus recovery and impurity depletion
- conclude SCMA polishing
- introduce DSP for different HCV genotypes
- apply DSP to genotype 5a virus
- analyze virus recovery and impurity depletion
- conclude DSP for genotype 5a virus
- compare chromatography-based DSP to ultracentrifugation-based DSP
- describe ultracentrifugation-based DSP
- analyze recovery percentage of ultracentrifugation-based DSP
- describe chromatography-based DSP
- analyze recovery percentage of chromatography-based DSP
- compare recovery rates of both techniques
- analyze contamination of products
- conclude advantages of chromatography-based technique
- show next generation sequencing analysis
- show overview of viral recovery and impurity depletion
- describe SXC capture at pH 9
- describe SCMA polishing using TRIS buffer at pH 7.4
- analyze recoveries and depletions for genotype 1a and 5a HCV
- calculate normalized DNA contents
- analyze protein and DNA concentrations
- calculate protein and DNA depletion
- analyze DNA per 1.0E+08 IU/ml
- conclude HCV purification
- summarize DSP development
- highlight importance of avoiding freeze-thaw cycle
- analyze virus recovery and impurity depletion
- conclude SCMA polishing
- summarize DSP for different HCV genotypes
- conclude advantages of chromatography-based technique

